Key result
Review evaluates adjuvant aspirin versus placebo for survival in resected early-stage colorectal cancer.
Why the study?
Does aspirin improve disease-free survival and overall survival in patients with resected early-stage colorectal cancer?
Does aspirin improve disease-free survival and overall survival in patients with resected early-stage colorectal cancer?
This paper reviews the emerging genetic markers and persistent uncertainties regarding adjuvant aspirin therapy for early-stage colorectal cancer.
Answers are grounded in this paper and cite their sources.
Aspirin should not yet change practice in resected early-stage colorectal cancer; leaves open benefits by PIK3CA or PTGS-2 status.
Randomised clinical trials (RCTs) have recently been conducted in patients with resected early-stage colorectal cancer (CRC) to evaluate the effects of aspirin versus placebo on disease-free survival (DFS) and overall survival (OS), particularly among those with tumours harbouring mutations in phosphatidylinositol 3-kinase (PI3K) pathway genes (most notably in the PIK3CA gene) or PTGS-2 (COX-2; cyclooxygenase-2) overexpression (Table 1).1–3
No takes yet. Share an insight, caveat, or question.
Patrignani et al. (2026) conducted a review in Resected early-stage colorectal cancer (CRC). Aspirin vs. Placebo was evaluated on Disease-free survival (DFS) and overall survival (OS). Recent randomized clinical trials have evaluated the effects of adjuvant aspirin versus placebo on survival in patients with resected early-stage colorectal cancer.
Synapse has enriched 10 related papers. Consider them for comparative context: